Molecular cloning of a cDNA encoding synaptic vesicle protein 2 (SV2) revealed that it is homologous to a family of proton cotransporters from bacteria and fungi and to a related family of glucose transporters found in mammals.
Efforts to understand the molecular events underlying neural secretion have focused on characterizing molecules unique to synaptic structures. To date, several synaptic vesicle proteins have been characterized (1) (2) (3) . One of these proteins, synaptic vesicle protein 2 (SV2), was originally identified with a monoclonal antibody generated against cholinergic vesicles from the electric organ of the electric ray Discopyge ommata (4) . The epitope recognized by this antibody was found to be present on secretory vesicles of all neural and endocrine cells surveyed (5) (6) (7) . Its presence across a wide range of species, from elasmobranchs to mammals, suggests that it plays a critical role in vesicle functioning.
cDNAs encoding SV2 were cloned by screening a rat brain library with DNA probes based on amino acid sequence (8) and by screening for immunoreactivity in CHO cells transfected with PC-12 cell cDNAs (9) . Both methods identified the same cDNA sequence. The predicted protein has 12 putative membrane-spanning domains and shows significant homology to a large family of transport proteins. Included in this family are bacterial and fungal proteins that cotransport protons with sugars, citrate, and drugs, and mammalian facilitative glucose transporters (10, 11) . The similarity to a large class of transport proteins suggested that SV2 might be a transporter specific to synaptic vesicles. The transport of neurotransmitters into vesicles is dependent on a proton gradient across the vesicle membrane (12) . Given that the activity of bacterial transporters homologous to SV2 also requires a proton gradient, it seemed possible that SV2 might be a neurotransmitter transporter.
The occurrence ofthe SV2 antigen in a wide range ofneural and endocrine cells suggested either that the SV2 antigen defines a family of proteins or that any transport activity of SV2 is generic to all secretory vesicles. To address the first possibility, that the SV2 cDNA is one of a family of related gene products, we looked for related proteins by screening a rat brain library with the region of SV2 most homologous to the bacterial transporters. We report here a cDNA sequence that encodes a protein recognized by the anti-SV2 antibody, which we denote SV2B.t MATERIALS AND METHODS Materials. Taq DNA polymerase was purchased from Boehringer Mannheim, radiolabeled nucleotides were from DuPont, and NucTrap push columns were from Stratagene.
The rat brain cDNA library used was from Stratagene, and the pCMV vector was from Invitrogen. Paraformaldehyde was purchased from EM Sciences. Sequenase (United States Biochemical) reagents were used for DNA sequencing. Rhodamine-conjugated goat anti-mouse secondary antibody was purchased from Tago. RNA Stat-60 was purchased from Tel Test "B" (Friendswood, TX). Enhanced chemiluminescence antibody detection reagents were from Amersham. RNA size standards were from BRL. Nylon membrane was purchased from Schleicher & Schuell.
Generation of a Probe and Library Screening. To generate a probe recognizing the first six membrane domains of SV2, a PCR was done using 24-nucleotide primers coding for amino acids 164-171 and 352-359. SV2 in SK-(4 fmol) was amplified in a reaction mixture containing 0.3 ,uM primers; 3.3 ,uM each dTTP, dGTP, and dATP; reaction buffer (provided by the manufacturer); 0.5 unit of Taq DNA polymerase; and 500 ,uCi [32P]dCTP (3000 Ci/mmol; 1 Ci = 37 GBq; 3.3 ,uM). Primers were annealed at 50°C for 1 min. Thirty amplification cycles were done followed by a 10-min extension reaction. The radiolabeled products were separated from other reaction constituents by NucTrap push column purification.
This probe was used to screen a Lambda ZAP II rat brain cDNA library by standard techniques (13) . Filters were hybridized at 55°C in 1.2 M salt [6x standard saline citrate (SSC)]. Thirty-nine positive clones were isolated. To determine which were reisolates of SV2, sequencing reactions were done using an oligonucleotide primer made to an internal region of SV2. Clones identified as novel were sequenced by the dideoxynucleotide chain-termination reaction.
Transient Expression of SV2B in COS Cells. The SV2B cDNA was subcloned into the pCMV expression vector. Plasmid DNA was purified by Triton lysis followed by a double cesium chloride gradient procedure (13) . COS cells, plated on two-chambered slides, were transfected with 10 ug ofplasmid DNA using the DEAE-dextran method (19) . Three days after transfection, the cells were processed for anti-SV2 immunoreactivity.
Immunohistochemistry. min and rinsed three times in PBS with 0.1 M glycine. Cells were permeabiized in PBS with 1% bovine serum albumin, 2% normal goat serum, and 0.4% saponin (blocking buffer) and then incubated with the anti-SV2 antibody in blocking buffer for 1 hr. Unbound antibody was removed with three PBS/glycine washes. The anti-SV2 antibody was labeled with secondary rhodamine-conjugated goat anti-mouse antibody.
Western Blot Analyses. Transfected cells were homogenized in 10 mM Hepes, pH 7.5/0.32 M sucrose using a metal Dounce homogenizer chilled on ice. Unbroken cells and nuclei were sedimented at 250 x g for 5 min, after which protein content of the supernatant (homogenate) was determined by the Bio-Rad protein assay with bovine serum albumin as a standard. Twenty-five micrograms of each homogenate was loaded onto an 8-12.5% gradient gel. Also loaded was -0.5 ,g of synaptic vesicle protein purified from rat brain (8) . Gel-resolved proteins were transferred to nitrocellulose and probed with affinity-purified anti-SV2 ascites fluid at 1:1000. Antibody binding was detected with a goat anti-mouse secondary antibody coupled to horseradish peroxidase that was used with an enhanced chemiluminescence kit.
Northern Isolation of a cDNA Encoding a Second Form of SV2. To identify other forms of SV2, we screened a rat brain cDNA library with DNA encoding the first six transmembrane domains. This region of SV2 contains the consensus sequences that define the bacterial transporter family (10) with which SV2 shares homology. We reasoned that related proteins would contain these conserved sequences. Screening -500,000 plaques at low stringency produced 25 reisolates of SV2. Sequencing reactions utilizing a primer from the coding region revealed a single base difference in all 25 reisolates when compared to the original clone. This difference results in a change from phenylalanine to cysteine at amino acid 342. Sequencing in entirety a SV2 clone isolated in this screen revealed no other differences. In addition to SV2, four other clones encoding a protein similar to SV2 were isolated. The longest of the four was chosen for analysis and sequenced on both strands. The nucleic and predicted amino acid sequences are shown in Fig.  1 . The 3660-nucleotide cDNA encodes a 682-amino acid protein with a predicted molecular mass of 77.5 kDa. Like SV2, this protein has an acidic N terminus with no apparent signal sequence, 12 predicted membrane-spanning domains, and 3 consensus sites for N-glycosylation. BESTFIT (16) alignment withSV2 revealed 65% identity and 78% similarity to SV2. Based on these similarities, we term this cDNA and the protein it encodes SV2B and will refer to the originalSV2 as SV2A.
The region of SV2B showing the most divergence from SV2A is the N-terminal cytoplasmic tail (Fig. 2 ). SV2B has a shorter N terminus, lacking the first 39 amino acids of SV2A
and two other 9-amino acid segments in this region. The only other deletion in SV2B is a 2-amino acid stretch in the region between membrane domains 7 and 8, the second most divergent region of SV2B. This region contains 38% nonconservative substitutions. Other differences between the two proteins are scattered throughout and include many conservative changes. SV2 Consensus Sequences. Identical and highly conserved regions of protein families are often functionally important. Two shared features of the SV2 proteins deserve mention. The first is the conservation between SV2A and -B of the sugar transporter motifs. The consensus sequences used to define this family of transporters (10) include an RXGRR sequence between the second and third membrane domains, a PESPR sequence at the end of the sixth membrane domain, and a diffused motif that spans the fourth and fifth membrane domains. In SV2B, the RXGRR sequence is KXGRK, conservative changes which suggest that the presence of basic residues in these positions is definitive of the consensus sequence. Like SV2A, SV2B has two differences in the diffused motif at the same residues as in SV2A. In the sugar transporters the RXGRR and PESPR motifs are repeated in the second halfofthe proteins, supporting the hypothesis that they arose via internal duplication. While the homology between SV2 and the transporters is less apparent in the second half of SV2, there are modified versions of these two consensus sequences in the second half of both forms of SV2. The region between the 7th and 8th membrane domains (analogous to the region between the 2nd and 3rd membrane domains) contains an RXGRXR sequence in both SV2 proteins. Likewise, after the 12th membrane domain, both SV2
proteins have a PETK sequence, a variant of the PESPR sequence that is also found following the 12th membrane domain of the Escherichia coli arabinose and xylose transporters and the facilitative glucose transporter of mammalian hepatoma cells (10) . Therefore, the SV2 proteins, like sugar transporters, shows some evidence of internal duplication.
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labeling of immunoreactive
The immunoreactive peptide fragment used to obtain the cells was reticular, resembling the labeling of cells expressing amino acid sequence of SV2A was the N terminus of the SV2A. This suggests that SV2B, like SV2A, is segregated to protein, suggesting that the epitope recognized by the antiintracellular membranes. Western blot analyses of cellular SV2 antibody is in this region of the protein (8) . The finding protein indicated that unmodified SV2B has a lower apparent that the antibody recognizes both forms of SV2 suggests that molecular mass than unmodified SV2A, consistent with its the epitope lies within the 19-amino acids (SV2B amino acids smaller predicted size (Fig. 5) . The immunoreactivity of brain 36-54) that comprise the longest series of identical residues synaptic vesicles appears to be a sum of the SV2A and SV2B in the N termini of the SV2 proteins. and brain regions total RNA from various tissues was subjected to Northern analyses. To be certain that the probes for each form were specific, Southern analyses were done using the same hybridization conditions used for Northern analyses. The Southern blots indicated that the probes distinguished between the two forms of SV2 (Fig. 6A ). 18S and 28S RNA, detected by methylene blue staining, were used to compare the amount and integrity of the RNA (data not shown).
Probes directed against SV2B recognized an -5-kb message expressed in brain but not in nonneural tissues (Fig. 6B) . The SV2B message is somewhat larger than the message coding for SV2A (-4 kb). It was surprising that neither SV2A nor -B was found in adrenal or pituitary (data not shown). It may be that SV2 is expressed at much lower levels in these tissues than it is in brain or that there is an endocrine-specific form of SV2.
A survey of different brain regions revealed that SV2A is expressed across all regions with highest levels in the subcortex (basal ganglia, thalamus). SV2B is also expressed in all brain regions, but its highest levels were found in the hippocampus and cortex. Both forms were expressed at lowest levels in the spinal cord (Fig. 6C) . The exposure shown in Fig. 6C was selected to best demonstrate differential expression; however, longer exposures revealed that both forms are found at significant levels in all regions.
DISCUSSION
The monoclonal antibody that defines SV2 recognizes a component of all secretory vesicles in neural and endocrine cells, suggesting that SV2 has a generic role in vesicle functioning. cDNA cloning of SV2 revealed its homology to cDNA subcloned into the pCMV mammalian expression vector. Cells were also transfected with SV2A and with vector. Anti-SV2 immunoreactivity was assessed 3 days after transfection. Cells were transfected with SV2A (A), SV2B (B), or pCMV vector (C). Labeling of both SV2 proteins is reticular in nature, suggesting that both are segregated to intracellular membranes. (Bar = 50 ,um.) a large family of transport proteins. Synaptic vesicles contain several transport activities. They take up neurotransmitters, protons, chloride (to counteract the electrochemical gradient produced by proton uptake), ATP, and calcium. They also transport compounds that regulate their internal osmolarity (12) . The bacterial transporters homologous to SV2 require a proton gradient for activity, suggesting the possibility that SV2 might transport neurotransmitters, an activity that also requires a proton gradient. The anti-SV2 immunoreactivity suggested that SV2 might comprise a family of proteins each transporting a different class of transmitter. Our search for other forms of SV2 in brain revealed one other form. The second form of SV2, SV2B, is 65% identical to the form of SV2 first described (SV2A). Both forms are recognized by the anti-SV2 antibody and are expressed only in neural tissues. While the two forms are expressed somewhat differently across brain regions, both are present throughout, suggesting that their activities are similar if not identical.
Recently, two cDNAs encoding vesicular catecholamine transporters have been cloned (20) . Interestingly, while they possess no sequence homology to SV2, they are homologous to another family of bacterial transporters, suggesting that more than one class of vesicular transporter is of bacterial descent. Taken together, the finding that SV2 is not likely to constitute a large family, that catecholamine transporters belong to a different transporter family, and that SV2 occurs in most or all neurons, the only possible transmitter substrates are amino acids, which are found in almost every neuron and fall into two classes (excitatory and inhibitory).
The second half of SV2 has been reported to show homology to sodium-dependent neurotransmitter transporters that are located on the plasma membrane (9) . However, BESTFIT comparison of this region of SV2 to various regions of the y-taminobutyric acid transporter (21) show a similarity of minimal statistical significance (Z = 2 vs. Z = 7 for the similarity between SV2 and the bacterial transporters). In addition, the lineup that maximizes identities between SV2 and the plasma membrane transporter pairs predicted membrane-spanning regions of the plasma membrane transporters with regions of SV2 predicted to lie between membrane domains. Given this very weak homology, and the evidence of internal duplication in SV2, we conclude that there is no relationship between SV2 and currently characterized plasma membrane neurotransmitter transporters.
The differences between the two forms of SV2 are found primarily in the N-terminal region preceding the first membrane domain. The functional implications ofthese differences are unknown. Despite these differences, however, both SV2A and SV2B have a predominance of acidic residues in this region, often in series. Series of acidic residues are also found in a calcium-binding protein of sarcoplasmic reticulum (22) , suggesting that the SV2 proteins might bind calcium. However, calcium overlay experiments found no evidence of calcium binding by SV2A (S.M.B., unpublished observations).
Other synaptic vesicle-specific proteins also are present in two or three forms. These isoforms are assumed to have similar or identical functions (2) . The finding that brain contains two forms of SV2 suggests that, as assumed for the other synaptic vesicle proteins, both forms have a similar activity not specific to a single class of neurons.
